임상 인텔리전스 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the clinical intelligence market size is projected to expand from USD 9.51 billion in 2025 and USD 10.67 billion in 2026 to USD 19.02 billion by 2031, registering a CAGR of 12.25% between 2026 to 2031.

This report is Segmented by Type (CDSS, Population Health Management, Retrospective Performance Management & Predictive Analytics, and More), Component (Software, Services, Hardware), Deployment (Cloud-Based, On-Premise, Hybrid), End User (Hospitals, Healthcare Providers, Pharmacies, Other), & Geography (North America, Europe, Asia-Pacific, and More). Forecasts are Provided in Value (USD).

Global Clinical Intelligence Market Trends and Insights

Proliferation of EHR, Claims, and Clinical Data Lakes

The Clinical intelligence market is gaining structural support from a larger and more distributed clinical data base that now stretches across EHR systems, claims environments, and social determinants inputs. EHR adoption reached 83% across EU member states in 2024, which points to a much denser pool of longitudinal patient data for analytics and model development at institutional scale. The more important change is that health systems are building federated analytics layers that let them train models and run inference without moving raw records across institutional boundaries. That change reduces the tradeoff between speed and privacy, because organizations can shorten the path from data generation to clinical action while staying within HIPAA and GDPR guardrails. The Clinical intelligence market therefore favors vendors that can govern distributed data fabrics across multiple sources, because those platforms are better positioned than single-instance ingestion tools to support larger contracts and broader use cases.

Shift From Retrospective Reporting To Real-Time Clinical Actioning

The Clinical intelligence market is moving away from retrospective reporting tools built for administrative review and toward real-time systems that can influence decisions during the clinical encounter itself. CMS reported that the BPCI Advanced program reduced per-episode payments by USD 1,014 relative to baseline, with surgical episodes showing reductions of USD 1,694 per episode, which gives providers a measurable reason to adopt tools that act before variation turns into cost leakage. This is also changing who buys these platforms, because procurement is shifting from quality teams toward finance leaders and value-based contract teams that want visible savings during active performance windows. That raises the evidence threshold for the Clinical intelligence market, since broad dashboards without encounter-level resolution are less useful in contracts where timing matters. The result is a stronger preference for platforms that connect historical care patterns to immediate workflow guidance, especially in systems exposed to bundled payment and accountable care pressures.

Interoperability Friction Across Multi-Vendor Clinical Stacks

The Clinical intelligence market still faces a major execution barrier because semantic misalignment across EHR, claims, imaging, and other clinical data systems makes deployment slower and more expensive than many vendors suggest. A 2025 systematic review in Frontiers in Health Services found that uneven adoption of HL7 FHIR, SNOMED CT, and LOINC, along with API standardization gaps, continues to create workflow inefficiencies and decision delays. Multi-EHR integration burden across Epic, Oracle Health, and athenahealth, where each added source expands the number of data-handling branches and increases implementation effort. Governance efforts such as TEFCA in the United States and the European Health Data Space in Europe improve trust and access rules. Still, they do not fully resolve the semantic differences inside vendor-specific FHIR implementations. This means the Clinical intelligence market remains easier for large providers with internal engineering depth. At the same time, mid-sized systems face a longer time to value and a lower realized return on platform investment.

Other drivers and restraints analyzed in the detailed report include:

1. AI Copilot Adoption In Clinical Workflow Orchestration
2. Value-Based Care Contracting Requires Measurable Care Variation Reduction
3. Validation Burden For AI-Enabled Clinical Recommendations

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Clinical Decision Support Systems held 31.31% of the clinical intelligence market share in 2025, making this the largest type segment in the current revenue mix. That position reflects deep EHR workflow integration and payer-driven evidence-based prescribing requirements that make CDSS difficult for hospitals to avoid. In the Clinical intelligence market, embedded CDSS tools inside Epic and Oracle Health environments benefit from direct data proximity because recommendations can be generated from clinical events at the point of entry instead of after a data transfer lag. Population Health Management remains the second-largest type segment because risk-bearing organizations still need patient panel visibility, though fragmented cross-payer data flows continue to limit the full value of these tools in some markets. Quality Improvement and Performance Measurement Systems are also gaining ground where national quality registries and outcomes-based reimbursement frameworks require stronger reporting discipline, especially across European systems.

Retrospective Performance Management and Predictive Analytics is the fastest-growing type segment, with a 15.38% CAGR from 2026 to 2031, and that pace is well above the broader Clinical intelligence market. This growth reflects demand from providers that need to connect historical care variation with forward-looking cost and outcome forecasts inside active value-based contracts. A 2026 npj Digital Medicine study showing that automated pharmacogenomic recommendation systems can produce evidence-based outputs with speed and consistency that manual review processes cannot match. That matters for the Clinical intelligence industry because retrospective analytics tools are no longer confined to after-the-fact review and are increasingly being built to feed real-time decision support. The practical boundary between retrospective and encounter-level intelligence is therefore narrowing, which means buyers in the Clinical intelligence market are comparing these platforms more directly with CDSS tools than they did in earlier procurement cycles.

Software accounted for 56.24% of revenue in 2025, which kept it as the leading component across the Clinical intelligence market. Providers have continued to direct spending toward platforms that combine data ingestion, governance, analytics, and AI execution in one environment instead of stitching together disconnected tools. That revenue lead is reinforced by subscription licensing and bundling strategies that tie applications to core data infrastructure, which deepens workflow dependence over time. Hardware now represents a smaller portion of spending because more workloads are moving toward cloud environments, though high-performance computing still matters in selected genomics and imaging settings where local processing and data residency remain important. This structure shows that the Clinical intelligence market still monetizes primarily through platforms, even as implementation depth becomes a bigger part of customer value.

Services is the fastest-growing component, with a 16.52% CAGR from 2026 to 2031, because many organizations can buy software but still lack the operating readiness needed to extract value from it. A wide gap in data science capability, workflow redesign capacity, and managed analytics support across the provider landscape. It also referenced UnitedHealth Group's USD 1.5 billion AI investment commitment for 2026 as a sign that large integrated players can internalize capabilities that smaller systems still need to source from external partners. In the Clinical intelligence industry, services work tied to pharmacogenomics integration, multi-source data governance, and workflow embedding carries greater strategic value than legacy reporting setup. That is why the Clinical intelligence market is seeing a stronger services layer emerge around implementation, optimization, and change management rather than around simple technical deployment alone.

Complete Report Scope:

• By Type
  • Clinical Decision Support Systems
  • Population Health Management
  • Retrospective Performance Management and Predictive Analytics
  • Clinical Benchmarking
  • Quality Improvement and Performance Measurement Systems
• By Component
  • Software
  • Services
  • Hardware
• By Deployment
  • Cloud-Based
  • On-Premise
  • Hybrid
• By End User
  • Hospitals
  • Healthcare Providers
  • Pharmacies
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 43.61% of the clinical intelligence market share in 2025, which made it the largest regional contributor to revenue. The region benefits from dense value-based care infrastructure, a mature EHR base, and concentrated technology investment by integrated health systems. The United States remains the largest country market because CMS payment models place direct financial consequences on unmanaged care variation and create clear demand for real-time clinical support at the encounter level. Oracle said in March 2026 that its Oracle Health Clinical AI Agent had generated savings of more than 200,000 physician hours across U.S. deployments, and AtlantiCare reported a 41% reduction in documentation time, which gives buyers a tangible workflow benchmark when they assess the Clinical intelligence market. Canada and Mexico add incremental demand, with Canadian provincial systems using predictive analytics to manage elective backlog and long-term care pressure tied to aging demographics.

Europe is the second-largest regional block in the Clinical intelligence market, and Germany and the United Kingdom stand out as the most important growth poles within the region. Germany's GEMEINSAM DIGITAL 2026 strategy, published in February 2026, targets AI-supported clinical documentation in more than 70% of health and care facilities by 2028 and aims to raise active electronic patient record users from 4 million to 20 million by 2030. France's July 2025 national strategy on AI and health data identified automated clinical documentation as the highest-priority near-term AI use case and linked it to sovereign data hosting and European Health Data Space preparation. The United Kingdom is accelerating replacement of legacy analytics systems through NHS interoperability demands, while Italy and Spain remain mid-tier markets where public digitization programs are creating early demand for population health management and benchmarking tools.

Asia-Pacific is the fastest-growing regional segment in the Clinical intelligence market, with a 16.15% CAGR from 2026 to 2031. Government-led health digitization across China, India, South Korea, Australia, and Japan is building a stronger base for analytics adoption and workflow automation. India's National Digital Health Mission is expanding the addressable environment for population health tools by standardizing health identifiers and strengthening the data foundation for AI-linked community health interventions. South Korea's connected hospital investment and Japan's aging population are supporting demand for predictive tools in chronic disease management and elder care. In the Middle East and Africa, the Gulf states lead adoption, and Oracle, Cleveland Clinic, and G42 announced a strategic partnership in May 2025 to launch an AI-based global healthcare delivery platform centered in the UAE, which shows that the Clinical intelligence market is also being treated as a sovereign capability in the region. South America remains a smaller but growing contributor, with Brazil and Argentina moving from EHR buildout toward analytics-led care management through hospital systems and expanding private health plan networks.

1. Athenahealth
2. CitiusTech
3. eClinicalWorks
4. Epic Systems
5. GE HealthCare Technologies Inc.
6. Health Catalyst, Inc.
7. IBM
8. Intersystems
9. IQVIA
10. Koninklijke Philips
11. Meditech
12. NextGen Healthcare
13. Oracle
14. Siemens Healthineers
15. United Health Group
16. Veradigm Inc.
17. Wolters Kluwer

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Proliferation of EHR, Claims, And Clinical Data Lakes
  • 4.2.2 Shift From Retrospective Reporting To Real-Time Clinical Actioning
  • 4.2.3 AI Copilot Adoption In Clinical Workflow Orchestration
  • 4.2.4 Value-Based Care Contracting Requires Measurable Care Variation Reduction
  • 4.2.5 Pharmacogenomics and Precision Medicine Content Expansion
  • 4.2.6 Cross-Enterprise Data Fusion For Trial Matching and Evidence Generation
• 4.3 Market Restraints
  • 4.3.1 Interoperability Friction Across Multi-Vendor Clinical Stacks
  • 4.3.2 Validation Burden For AI-Enabled Clinical Recommendations
  • 4.3.3 Workflow Alert Fatigue and Low Physician Trust in Black-Box Scores
  • 4.3.4 Budget Compression and Long Sales Cycles In Provider Organizations
• 4.4 Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Type
  • 5.1.1 Clinical Decision Support Systems
  • 5.1.2 Population Health Management
  • 5.1.3 Retrospective Performance Management and Predictive Analytics
  • 5.1.4 Clinical Benchmarking
  • 5.1.5 Quality Improvement and Performance Measurement Systems
• 5.2 By Component
  • 5.2.1 Software
  • 5.2.2 Services
  • 5.2.3 Hardware
• 5.3 By Deployment
  • 5.3.1 Cloud-Based
  • 5.3.2 On-Premise
  • 5.3.3 Hybrid
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Healthcare Providers
  • 5.4.3 Pharmacies
  • 5.4.4 Other End Users
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 athenahealth, Inc.
  • 6.3.2 CitiusTech Inc.
  • 6.3.3 eClinicalWorks, LLC
  • 6.3.4 Epic Systems Corporation
  • 6.3.5 GE HealthCare Technologies Inc.
  • 6.3.6 Health Catalyst, Inc.
  • 6.3.7 International Business Machines Corporation
  • 6.3.8 InterSystems Corporation
  • 6.3.9 IQVIA Holdings Inc.
  • 6.3.10 Koninklijke Philips N.V.
  • 6.3.11 MEDITECH
  • 6.3.12 NextGen Healthcare, Inc.
  • 6.3.13 Oracle Corporation
  • 6.3.14 Siemens Healthineers AG
  • 6.3.15 UnitedHealth Group Incorporated
  • 6.3.16 Veradigm Inc.
  • 6.3.17 Wolters Kluwer N.V.

7 Market Opportunities & Future Outlook

• 7.1 White-Space and Unmet-Need Assessment